What is the current stock price of Bio-Path Holdings, Inc. (BPTH)?

As of the latest market data, Bio-Path Holdings, Inc. (BPTH) is trading at $0.06. The stock has seen a loss of 0.00% today.

Does Bio-Path Holdings, Inc. (BPTH) pay a dividend?

Based on current data, Bio-Path Holdings, Inc. does not have a confirmed active dividend policy.

What is the market cap of Bio-Path Holdings, Inc.?

The current market capitalization of Bio-Path Holdings, Inc. (BPTH) is approximately unavailable.

BPTH

Bio-Path Holdings, Inc.·Healthcare

0.06

0.000%(+0.00)

Market Closed

0.06

4.833%(+0.00)

After Hours

Last Updated: — ET

52W L: $0.0552W H: $0.23

BPTH NEWS

defenseworld.net

Mar 20

Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX)

Turn Therapeutics (NASDAQ: TTRX - Get Free Report) and Bio-Path (NASDAQ: BPTH - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability. Profitability This table compares Turn Therapeutics and Bio-Path's

defenseworld.net

Jan 15

Critical Analysis: Amarillo Biosciences (OTCMKTS:AMAR) vs. Bio-Path (NASDAQ:BPTH)

Institutional and Insider Ownership 5.7% of Bio-Path shares are held by institutional investors. 34.4% of Amarillo Biosciences shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Profitability This

Company Profile

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2008-03-04

Beta

-0.33

Websitewww.biopathholdings.com↗